Terns Inc. has divulged glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of diabetes, obesity and liver diseases.

A new class of drugs is set ... But in March semaglutide (a GLP-1 receptor agonist sold as Ozempic for diabetes and Wegovy for weight-loss) was approved in America for cardiovascular disease ...

On October 21, Novo Nordisk announced positive news on the cardiovascular benefits of its oral glucagon-like peptide-1 receptor (GLP-1R) agonist, Rybelsus, which is currently approved for type 2 ...

The global GLP-1 receptor agonist market is poised for extraordinary expansion ... (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers ...

Opens in a new tab or window PHILADELPHIA -- Chest x-rays did not support the existence of an aspiration risk for surgical candidates using GLP-1 receptor agonists, according to a retrospective study.

Opens in a new tab or window Share on X ... The FDA has not approved any SGLT2 inhibitor or GLP-1 receptor agonist for type 1 diabetes, but their use in this patient population "may continue ...

It’s important to discuss your complete medical history with a health care provider before starting any new medication, including GLP-1 agonists ... Mounjaro have been approved for weight ...

The medicines regulator has urged GPs to be alert to signs of ‘misuse’ of GLP-1 receptor agonists for weight loss, such as semaglutide ... The Government said the drugs were not a ‘quick fix’ and ...

Some 12% — or about 1 in 8 — people living in the U.S. have tried a GLP-1 drug, according to a survey by the Kaiser Family Foundation. And with that drug comes many dietary changes that need ...